首页> 外文期刊>Japanese Journal of Ophthalmology >Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy
【24h】

Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy

机译:玻璃体腔注射贝伐单抗治疗中枢性浆液性脉络膜视网膜病变引起的医源性脉络膜新生血管

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Choroidal neovascularization (CNV) is well recognized as a complication of laser photocoagulation for central serous chorioretinopathy (CSC). However, little is known about its management. Patients: Two patients who developed iatrogenic CNV after laser photocoagulation for CSC. Observations: A single intravitreal bevacizumab (IVB) injection was given in both cases. The best-corrected visual acuity (BCVA) of 1 of the patients improved from 0.3 to 0.5 on the following day and to 1.2 three months after the IVB, and the BCVA of the other patient improved from 0.5 to 1.0 two weeks after the IVB. In both cases, the CNV became inactive 1 month after IVB on fluorescein angiography and remained stable for over 1 year. Conclusion: IVB was beneficial for iatrogenic CNV that developed after laser photocoagulation for CSC.
机译:背景:脉络膜新生血管形成(CNV)是公认的中心性浆液性脉络膜视网膜病变(CSC)的激光光凝并发症。但是,对其管理知之甚少。患者:两名患者在接受CSC激光光凝后产生了医源性CNV。观察:在两种情况下均单次注射玻璃体内贝伐单抗(IVB)。 IVB后两天,其中1位患者的最佳矫正视力(BCVA)从第二天的0.3改进到0.5,在IVB后3个月改进到1.2,另一名患者的BCVA从0.5改进到1.0。在这两种情况下,在进行荧光素血管造影IVB后1个月,CNV均失活,并保持稳定超过1年。结论:IVB对CSC激光光凝后产生的医源性CNV有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号